Journal of Dermatology最新文献

{"title":"Japanese Dermatological Association's Clinical Practice Guidelines for Alopecia Areata 2024: A Complete English Translated Version","authors":"Manabu Ohyama,&nbsp;Taisuke Ito,&nbsp;Yasuyuki Amoh,&nbsp;Shigeki Inui,&nbsp;Hisayoshi Imanishi,&nbsp;Rie Ueki,&nbsp;Masaki Uchiyama,&nbsp;Koya Obara,&nbsp;Misaki Kinoshita-Ise,&nbsp;Teruki Dainichi,&nbsp;Yohei Natsuaki,&nbsp;Ryota Hayashi,&nbsp;Kazutoshi Harada,&nbsp;Masahiro Fukuyama,&nbsp;Masato Mizuashi,&nbsp;Yutaka Shimomura","doi":"10.1111/1346-8138.17859","DOIUrl":"10.1111/1346-8138.17859","url":null,"abstract":"<p>This is an English-translated version of the Japanese Dermatological Association's clinical practice guidelines for alopecia areata (AA) 2024. It includes the sections of summary, pathogenesis and epidemiology, evaluation and diagnosis, and treatment of AA. Updates based on recent evidence/advances were made in each part. The treatment part contains the statements of recommendation for 25 clinical questions (CQs) with respective recommendation/evidence levels. AA-cube, a graphic illustration conceptualizing the treatment strategy based on individual patients' factors, was newly proposed. Taking into account the recent approval of a JAK inhibitor and a JAK3/TEC family kinase selective inhibitor, a CQ for these modalities was also added. These guidelines aim to support evidence-based management of AA as well as prompt understanding of disease etiopathogenesis.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"e876-e907"},"PeriodicalIF":2.7,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17859","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Cross-Sectional Questionnaire Survey on the Impact of Congenital Ichthyosis on Lifelong Education and Career","authors":"Yuika Suzuki,&nbsp;Kana Tanahashi,&nbsp;Yumiko Kobayashi,&nbsp;Fumie Kinoshita,&nbsp;Chiaki Murase,&nbsp;Takuya Takeichi,&nbsp;Masashi Akiyama","doi":"10.1111/1346-8138.17879","DOIUrl":"https://doi.org/10.1111/1346-8138.17879","url":null,"abstract":"<div>\u0000 \u0000 <p>A cross-sectional analysis was conducted to evaluate the impact of ichthyosis symptoms on the educational achievement and career choices of adults, or the potential future impact on children. A total of 77 respondents completed a questionnaire assessing the degree to which ichthyosis had impacted, or was expected to impact, their education and career. Responses were categorized as “none,” “somewhat,” or “greatly.” The data were analyzed in relation to the objective severity measures in our previous study, including the Clinical Ichthyosis Score (CIS) and QOL assessments, using Spearman's correlation coefficients. Of the 77 participants, 45.5% reported a great impact, 41.6% reported some impact, and 13.0% reported no impact. A significant positive correlation was observed between the perceived impact and CIS (rs = 0.402, <i>p</i> &lt; 0.001), as well as between the perceived impact and QOL scores (16 ≤ age, rs = 0.462, <i>p</i> &lt; 0.001; 4 ≤ age ≤ 15, rs = 0.822, <i>p</i> &lt; 0.001; age ≤ 3, rs = 0.894, <i>p</i> = 0.106). Symptoms such as itching, pain, and social discomfort were identified as potential cumulative contributors to educational and occupational limitations. The findings suggest that higher disease severity and lower QOL are significantly associated with adverse educational and career outcomes in patients with congenital ichthyosis. (207/300 words).</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 9","pages":"1470-1474"},"PeriodicalIF":2.7,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Imatinib in Metastatic Esophageal Melanoma Harboring a KIT L576P (Exon 11) Mutation After Treatment Failure of Immune Checkpoint Inhibitors: A Case Report","authors":"Yoshiyuki Matsui,&nbsp;Eiji Nakano,&nbsp;Dai Ogata,&nbsp;Naoya Yamazaki,&nbsp;Kenjiro Namikawa","doi":"10.1111/1346-8138.17875","DOIUrl":"10.1111/1346-8138.17875","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"e921-e922"},"PeriodicalIF":2.7,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Rituximab Successfully Controlling SSc Vascular and Other Symptoms in a Pregnant Patient, Leading to a Safe Pregnancy and Delivery","authors":"Norika Akashi,&nbsp;Mariko Ogawa-Momohara,&nbsp;Satoshi Kamiya,&nbsp;Yuta Yamashita,&nbsp;Haruka Koizumi,&nbsp;Rina Inami,&nbsp;Takafumi Ushida,&nbsp;Takuya Takeichi,&nbsp;Yoshinao Muro,&nbsp;Masashi Akiyama","doi":"10.1111/1346-8138.17878","DOIUrl":"10.1111/1346-8138.17878","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"e919-e920"},"PeriodicalIF":2.7,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Free Tarsoconjunctival Grafts in Lower Eyelid Reconstruction Following Basal Cell Carcinoma Surgery","authors":"Tokiyoshi Ikoma,&nbsp;Yoko Amagata,&nbsp;Kazuyasu Fujii,&nbsp;Megumi Aoki,&nbsp;Takahisa Tozawa,&nbsp;Masashi Iwata,&nbsp;Kentaro Yamamura,&nbsp;Yui Hirano,&nbsp;Shoichi Sakamoto,&nbsp;Shigeto Matsushita","doi":"10.1111/1346-8138.17872","DOIUrl":"10.1111/1346-8138.17872","url":null,"abstract":"<div>\u0000 \u0000 <p>The treatment of skin malignancies of the lower eyelid presents unique challenges due to the thin skin, proximity to vital structures, and the functional importance of the eyelid. Although surgical excision remains the standard approach for such malignancies, lower eyelid reconstruction is critical for preserving both function and aesthetics. Free tarsoconjunctival grafts (FTGs) have emerged as effective options for posterior lamellar reconstruction, providing structural support and long-term stability. This retrospective study analyzed cases of lower eyelid reconstruction using FTGs between December 2014 and November 2024. Eleven cases met the inclusion criteria, all of which involved basal cell carcinoma (BCC). During this period, 115 lower eyelid BCC cases were treated, and FTGs were selectively applied in 9.6% of cases. Grafts were harvested from the ipsilateral upper eyelid, with dimensions ranging from 5 to 11 mm in width and 3 to 5 mm in height. Postoperative outcomes, including complications, graft dimensions, and tumor recurrence, were evaluated. No major complications were observed. Minor complications occurred in three cases: one patient developed trichiasis at the graft site, and two patients experienced mild corneal epithelial damage. However, none of the patients reported subjective symptoms related to these complications. At a mean follow-up of 19.3 months, no tumor recurrence was observed, although one patient died of unrelated causes. These findings highlight the suitability of FTGs for small to moderately sized defects. Careful graft size selection leads to favorable outcomes with minimal complications. Overall, FTGs are a reliable and safe option for lower eyelid reconstruction, balancing oncological safety, functional preservation, and aesthetic outcomes in conservative surgical approaches for BCC treatment.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 9","pages":"1465-1469"},"PeriodicalIF":2.7,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermoscopic Rosettes in Cutaneous Chronic Graft-Versus-Host Disease","authors":"Asuka Oikawa,&nbsp;Ken Natsuga,&nbsp;Mika Watanabe,&nbsp;Toshihiro Matsukawa,&nbsp;Hideyuki Ujiie","doi":"10.1111/1346-8138.17870","DOIUrl":"10.1111/1346-8138.17870","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"e917-e918"},"PeriodicalIF":2.7,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144677098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary Publication of Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Cutaneous Angiosarcoma 2025","authors":"Yasuhiro Fujisawa,&nbsp;Yasuo Yoshioka,&nbsp;Koji Yoshino,&nbsp;Taku Fujimura,&nbsp;Yoichi Naito,&nbsp;Mamiko Masuzawa,&nbsp;Kohei Oashi,&nbsp;Eiji Nakano,&nbsp;Hiroshi Kato,&nbsp;Yusuke Muto,&nbsp;Hiroshi Koga,&nbsp;Tomomitsu Miyagaki,&nbsp;Hiroshi Uchi,&nbsp;Yasuhiro Nakamura,&nbsp;Kenji Asagoe","doi":"10.1111/1346-8138.17856","DOIUrl":"10.1111/1346-8138.17856","url":null,"abstract":"<p>Cutaneous angiosarcoma is a rare aggressive malignancy with poor prognosis. Due to its rarity, high-level evidence from randomized controlled trials is limited, and treatment strategies have historically been adapted from other sarcomas. These guidelines aim to provide updated recommendations based on newly available evidence to standardize clinical practice in Japan. The 2024 revision was conducted under the Japanese Dermatological Association's commission, incorporating expert reviews and public comments. Given the lack of an established staging system, recommendations were formulated through systematic literature reviews and a structured consensus process. Five clinical questions were addressed, covering first-line chemoradiotherapy (CRT), management of residual lesions post-CRT, second-line treatment options, the role of pembrolizumab in tumor mutational burden-high cases, and treatment strategies for nonhead-and-neck angiosarcomas. Key recommendations include weakly recommending CRT for large (≥ 5 cm) nonmetastatic tumors, preferring drug modification over excision for residual lesions after CRT, and equally considering docetaxel, pazopanib, or eribulin for paclitaxel-resistant cases. Pembrolizumab was weakly recommended for tumor mutational burden-high cases. For radiation-associated angiosarcoma, surgical treatment was favored over CRT, while Stewart–Treves syndrome cases were treated similarly to head-and-neck angiosarcoma. Future directions emphasize the need for multicenter registry studies and prospective trials to refine treatment strategies. As advances in genomic medicine and immunotherapy evolve, guideline updates will be essential to ensure optimal patient care.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 10","pages":"e859-e875"},"PeriodicalIF":2.7,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17856","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pruritus Is an Indicator for Quality of Life in Cutaneous T-Cell Lymphoma","authors":"Andrea Roggo,&nbsp;Yves Wüest,&nbsp;Reinhard Dummer,&nbsp;Egle Ramelyte","doi":"10.1111/1346-8138.17847","DOIUrl":"10.1111/1346-8138.17847","url":null,"abstract":"<p>In cutaneous T-cell lymphoma (CTCL), chronic pruritus affects up to 94% of patients as a leading factor reducing quality of life (QoL). Traditional antipruritic medication does not show sufficient relief. Partly due to a lack of therapeutic options, pruritus is rarely assessed in a standardized manner within routine clinical practice. In this cross-sectional, single-institution study, we characterized CTCL-associated pruritus including perception, dynamics, and modifying factors. QoL was evaluated with the Dermatology Life Quality Index (DLQI) and EORTC core quality of life questionnaire (QLQ-C30). Patients with early-stage Mycosis fungoides (MF, <i>n</i> = 16), late-stage MF (<i>n</i> = 10) and Sézary syndrome (SS, <i>n</i> = 10), treated at the University Hospital of Zurich, completed all three questionnaires. 80.5% (<i>n</i> = 29/36) patients reported disease-associated pruritus worsening with stress (51.7%, <i>n</i> = 15/29), scratching (37.9%, <i>n</i> = 11/29), and sweating or exercise (31.0%, <i>n</i> = 9/29). DLQI was associated with CTCL-specific skin involvement (modified severity-weighted assessment tool, mSWAT) (ρ = 0.44, <i>p</i> &lt; 0.01), worst experienced pruritus (<i>ρ</i> = 0.42, <i>p</i> = 0.04) and current perceived pruritus (<i>ρ</i> = 0.60, <i>p</i> &lt; 0.01). Summarizing those three factors in a Pruritus-Score correlated strongly with DLQI (<i>ρ</i> = 0.71, <i>p</i> &lt; 0.01), QLQ-C30 global health status (<i>ρ</i> = −0.71, <i>p</i> &lt; 0.01) as well as fatigue (<i>ρ</i> = 0.50, <i>p</i> = 0.02). Our results confirm the relevance of pruritus in CTCL. The Pruritus-Score outperforms solely assessment of present pruritus in identifying patients who might experience related impairments in QoL. It quantifies this complex symptom in three factors that can be collected in clinical practice. This Pruritus-Score can support consideration of pharmaceutical and non-pharmaceutical approaches aimed at addressing reductions in quality of life and associated symptoms such as fatigue.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 9","pages":"1404-1410"},"PeriodicalIF":2.7,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17847","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oedematous Erythematous Plaques Masking an Important Infection","authors":"Wei Qiang Chng,&nbsp;Martin T.W. Chio","doi":"10.1111/1346-8138.17864","DOIUrl":"10.1111/1346-8138.17864","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 9","pages":"e815-e816"},"PeriodicalIF":2.7,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial","authors":"Jianzhong Zhang,&nbsp;Yangfeng Ding,&nbsp;Ping Wang,&nbsp;Linfeng Li,&nbsp;Weili Pan,&nbsp;Yan Lu,&nbsp;Hao Cheng,&nbsp;Xian Jiang,&nbsp;Ji-Chen Ho,&nbsp;Shuping Guo,&nbsp;Seong Jun Seo,&nbsp;Linda Stein Gold,&nbsp;Andrew Blauvelt,&nbsp;Joe Zhuo,&nbsp;Yichen Zhong,&nbsp;Brandon Becker,&nbsp;Leona Liu,&nbsp;Subhashis Banerjee,&nbsp;Diamant Thaçi","doi":"10.1111/1346-8138.17834","DOIUrl":"10.1111/1346-8138.17834","url":null,"abstract":"<p>POETYK PSO-3, a 52-week, double-blind, phase 3 study, evaluated the efficacy and safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in adult patients with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea. Secondary and additional endpoints included improvement on two patient-reported outcome measures: the Psoriasis Symptoms and Signs Diary (PSSD) total score and the Dermatology Life Quality Index (DLQI). Patients were randomized 1:2 to placebo or deucravacitinib 6 mg once daily; at week 16, patients receiving placebo crossed over to receive deucravacitinib. PSSD and DLQI score changes from baseline and response rates for achieving meaningful within-patient change from baseline in PSSD total score (≥ 15 points) and DLQI of 0 or 1 (DLQI 0/1) were assessed over 52 weeks. In POETYK PSO-3, 74 patients were randomized to placebo and 146 patients to deucravacitinib. At week 16, mean (95% confidence interval [CI]) PSSD total score changes from baseline were −1.9 (−6.9, 3.1) and −28.8 (−32.6, −25.0) in patients receiving placebo and deucravacitinib, respectively. At both weeks 16 and 52, the response rate for ≥ 15-point meaningful change in PSSD total score (95% CI) was 73.3% (65.3, 80.3) in the group randomized to deucravacitinib. At week 16, mean (95% CI) DLQI changes from baseline were −1.7 (−3.1, −0.4) and −7.4 (−8.4, −6.4) in patients receiving placebo and deucravacitinib, respectively. In patients randomized to deucravacitinib, DLQI 0/1 response rates (95% CI) at weeks 16 and 52 were 36.4% (28.5, 44.4) and 44.7% (36.5, 52.9), respectively. Deucravacitinib was associated with meaningful and sustained improvements in psoriasis symptoms and signs and in quality of life in Asian patients with moderate to severe plaque psoriasis.</p><p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT04167462</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 9","pages":"1360-1367"},"PeriodicalIF":2.7,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17834","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}